Abstract-The ample expression of chemokines and their receptors by neurons in the brain suggests that they play a functional role beyond the coordination of inflammatory and immune responses. Growing evidence implicates brain chemokines in the regulation of neuronal activity and neurohormonal release. This study examined the potential role of brain chemokines in regulating hemodynamic, sympathetic, and neuroendocrine mechanisms in rats with ischemiainduced heart failure (HF). Immunohistochemical analysis revealed that the chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12 was highly expressed in the hypothalamic paraventricular nucleus and subfornical organ and that SDF-1 expression was significantly increased in HF rats compared with sham-operated (SHAM) control rats. ICV injection of SDF-1 induced substantial and long-lasting increases in blood pressure, heart rate, and renal sympathetic nerve activity in both SHAM and HF rats, but responses were exaggerated in HF rats. Bilateral microinjection of SDF-1 into the paraventricular nucleus also elicited exaggerated increases in blood pressure, heart rate, and renal sympathetic nerve activity in the HF rats. A 4-hour ICV infusion of SDF-1 increased plasma levels of arginine vasopressin, adrenocorticotropic hormone, and norepinephrine in normal rats, responses that were prevented by pretreatment with ICV SDF-1 short-hairpin RNA (shRNA). ICV administration of SDF-1 shRNA also reduced plasma arginine vasopressin, adrenocorticotropic hormone, and norepinephrine levels in HF rats. These data suggest that the chemokine SDF-1, acting within the brain, plays an important role in regulating sympathetic drive, neuroendocrine release, and hemodynamic function in normal and pathophysiological conditions and so may contribute to the neural and humoral activation in HF. Key Words: brain Ⅲ chemokines Ⅲ sympathetic nervous system Ⅲ neurohumoral activation Ⅲ hypothalamic paraventricular nucleus Ⅲ subfornical organ Ⅲ heart failure R ecent studies have identified numerous physiological and pathophysiological functions of chemokines, beyond their traditionally recognized role as chemoattractants.
ecent studies have identified numerous physiological and pathophysiological functions of chemokines, beyond their traditionally recognized role as chemoattractants. 1 More than 50 chemokines and 20 chemokine receptors have been identified, and more than half of those are represented in the central nervous system. 2 Chemokines and their G proteincoupled receptors are constitutively expressed by astrocytes, microglia, and neurons in physiological and pathological states. 2, 3 Within the central nervous system, chemokines have been implicated in development, neuroinflammation, dendritic differentiation, synaptic transmission, and neuroendocrine regulation. 4, 5 They have been reported to regulate the electrical activity of neurons and the release of neurotransmitters and neuropeptides, including glutamate, ␥-aminobutyric acid, dopamine, serotonin, opioids, and cannabinoids. 6, 7 Of particular interest to our laboratory, which has previously demonstrated a significant contribution of central inflammation to sympathetic nerve activity in systolic heart failure (HF), 8, 9 chemokines and their receptors are present in several key cardiovascular regulatory regions of the brain, the hypothalamic paraventricular nucleus (PVN), the supraoptic nucleus (SON), and the subfornical organ (SFO), that have been implicated in the pathophysiology of HF. The present study was designed to determine whether chemokines in these brain regions contribute to neurohumoral activation in HF.
The chemokines are a large subfamily of the cytokines. Some are proinflammatory and some are anti-inflammatory in nature. 10, 11 In view of their numbers, their receptor promiscuity, and their pleiotropic actions, efforts to define the contribution of any one chemokine to an inflammatory state like HF (eg, by blocking its effects) would seem futile. On the other hand, a reasonable indication of the central influence of a particular chemokine in HF might be determined by manipulating its levels in cardiovascular regions of the brain. For that purpose, we chose to study the effects of the proinflammatory chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12, a member of the CXC subfamily. SDF-1 has only 1 known receptor, 12 for which a selective antagonist is available, and is known to regulate the release of arginine vasopressin (AVP), 5 a function of neurons found only in the PVN and SON. In support of this choice, our preliminary studies demonstrated the presence of SDF-1 and its CXCR4 receptor in neurons and glial cells of the PVN, SFO, and SON.
Methods Animals
Adult male Sprague-Dawley rats, weighing 275 to 325 g, were purchased from Harlan Sprague Dawley. The animals were housed in temperature-controlled (23Ϯ2°C) rooms at the University of Iowa Animal Care Facility and fed rat chow ad libitum. All of the experimental procedures were approved by the University of Iowa Institutional Animal Care and Use Committee. The experimental protocols were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
HF and sham-operated (SHAM) rats were prepared as described previously. 13 The experimental protocols below were conducted Ϸ4 weeks after induction of HF or sham operation.
Experimental Protocols

SDF-1 and CXCR4 Expression in PVN and SFO
SHAM (nϭ6) and HF (nϭ6) rats were euthanized and transcardially perfused with heparinized saline followed by 4% paraformaldehyde in 0.01 mol/L of PBS. The collected brains were cut into 16-micron coronal sections for immunofluorescent studies to examine the expression of SDF-1 and its receptor CXCR4 in PVN and SFO.
Quantification of SDF-1 and CXCR4 in PVN and SFO
SHAM (nϭ6) and HF (nϭ6) rats were anesthetized with urethane and decapitated immediately. The brain tissues were rapidly removed and frozen in liquid nitrogen. The PVN (including some surrounding tissue) and the SFO were harvested to measure the protein level of SDF-1 and CXCR4 by Western blot.
Hemodynamic and Sympathetic Effects of SDF-1
SHAM (nϭ24) and HF (nϭ24) rats were anesthetized and prepared for electrophysiological and hemodynamic recordings to determine the effects of ICV administration (25 or 100 ng in 2 L) or bilateral PVN microinjection (2.5 or 5.0 ng in 0.2 L in each side) of SDF-1 on renal sympathetic nerve activity (RSNA), blood pressure (BP), and heart rate (HR). SDF-1 for ICV injection or direct PVN microinjection was dissolved in artificial cerebrospinal fluid, which served as vehicle.
Neuroendocrine Effects of SDF-1
Neuroendocrine effects of SDF-1 were assessed in the following treatment groups: (1) SHAM (nϭ6) and HF (nϭ6) rats treated with ICV vehicle (10 L/h for 4 hours); (2) normal rats pretreated 1 week earlier with ICV SDF-1 short-hairpin RNA (shRNA) lentiviral particles (nϭ6) or a scrambled shRNA (nϭ6) and then treated with ICV SDF-1 (50 ng/10 L/h for 4 hours); and (3) HF rats pretreated 1 week earlier with ICV SDF-1 shRNA lentiviral particles (nϭ6) or a scrambled shRNA (nϭ5). Rats were euthanized to collect trunk blood samples into EDTA tubes for ELISA assay of AVP, adrenocorticotropic hormone (ACTH), and norepinephrine (NE; as an indicator of sympathetic activation). Hemodynamic and molecular variables were also measured in the shRNA groups.
Specific Materials and Methods
Specific materials and methods are available in the online-only Data Supplement.
Statistical Analysis
The significance of differences among groups was analyzed by 2-way repeated-measure ANOVA followed by post hoc Fisher test. For other unpaired data, a Student t test was used for comparison between groups. PϽ0.05 was considered to indicate statistical significance.
Results
Echocardiographic Assessment of HF
The HF animals assigned to each group were well matched with regard to echocardiographically defined left ventricular systolic function. The estimated size of the ischemic zone and the left ventricular ejection fraction were not different in HF rats assigned to the different treatment groups. Only animals with large infarctions (estimated size of the ischemic zone, Ͼ35%) were used in this study. Compared with SHAM rats, left ventricular end-diastolic volume was increased and left ventricular ejection fraction was reduced in the HF rats. (Table S1 , available in the online-only Data Supplement).
SDF-1 and CXCR4 Expression in PVN and SFO
Immunofluorescent studies revealed intense expression of SDF-1 immunoreactivity in PVN and SFO (Figure 1 ) of both SHAM and HF rats. In PVN, SDF-1 was expressed in all 4 of the commonly recognized subdivisions, 14 the dorsal parvocellular, the ventrolateral parvocellular, the medial parvocellular, and the posterior magnocellular. The ventrolateral parvocellular and posterior magnocellular subdivisions had higher densities of SDF-1-like immunoreactivity than dorsal parvocellular and medial parvocellular subdivisions in both SHAM and HF rats. In SFO, SDF-1 was evenly expressed throughout the nucleus. In HF rats, compared with SHAM, SDF-1-like immunoreactivity was more intense (HF versus sham, PϽ0.05) in both PVN and SFO ( Figure 1A and 1C) . The Western blot analysis confirmed a substantially higher (PϽ0.05) expression of the SDF-1 in the PVN (Figure 2A ) and SFO ( Figure 2C ) of HF rats compared with SHAM rats.
Confocal immunofluorescent images indicated that SDF-1 receptor CXCR4 was abundantly expressed in both PVN and SFO. However, in contrast to its ligand, CXCR4 immunofluorescent reactivity was not increased in the PVN and SFO of HF rats, compared with SHAM rats (Figure 1B and 1C) . Similarly, Western blot revealed no significant difference in the level of CXCR4 in PVN ( Figure 2B ) and SFO ( Figure 2D ) of HF rats compared with SHAM rats.
Cellular Localization of SDF-1 and CXCR4
Both SDF-1 and CXCR4 were expressed in the neurons and glial cells in the PVN and SFO. Figure S1 shows the expression of SDF-1 and CXCR4 in PVN neurons and astrocytes, and Figure S2 shows SDF-1 in microglia of the PVN.
In the PVN, SDF-1 immunoreactivity colocalized with AVP immunoreactivity in neurons of the posterior magnocellular ( Figure 3A ) and with corticotrophin-releasing hormone (CRH) immunoreactivity in medial parvocellular neu-rons ( Figure 3B ). Colocalization of SDF-1 with AVP or CRH expression was found in both SHAM and HF rats.
Hemodynamic and Sympathetic Effects of SDF-1
In SHAM rats (nϭ6), ICV injection of SDF-1 at the dose of 25 ng had no effect on mean BP (MBP), HR, or RSNA ( Figure 4A and 4E) . In HF rats (nϭ6; Figure 4C and 4E), however, the same dose of SDF-1 increased MBP (from 95.2Ϯ3.1 to 112.3Ϯ3.7 mm Hg), HR (321Ϯ10 to 359Ϯ9 bpm), and RSNA (54.2Ϯ6.5% change in integrated RSNA, from a baseline of 20.3Ϯ2.4 mV), measured at 3 hours. The higher 100 ng ICV dose of SDF-1 induced increases in MBP, HR, and RSNA in the SHAM rats (nϭ6; Figure 4B ) and greater increases in the HF rats (nϭ6; Figure 4D 
Neuroendocrine Effects of SDF-1
In HF rats treated with ICV vehicle (nϭ6), the plasma levels of AVP ( Figure 6A ), ACTH ( Figure 6B ), and NE ( Figure 6C ) were 2 to 3 times higher compared with ICV vehicle-treated SHAM rats (nϭ6). In HF rats pretreated a week earlier with ICV SDF-1 shRNA, plasma AVP, ACTH, and NE levels were significantly lower compared with the HF rats treated with a scrambled shRNA control (nϭ5; Figure 6 ). The MBP of HF rats pretreated with SDF-1 shRNA was not significantly different from that of HF rats treated with the control shRNA (92.1Ϯ3.8 versus 87.3Ϯ3.6 mm Hg), but HR was significantly lower (316Ϯ8 versus 342Ϯ7 bpm; PϽ0.05).
In normal rats pretreated with a scrambled control shRNA, a 4-hour ICV infusion of SDF-1 (50 ng/h; nϭ6) significantly augmented the plasma levels of AVP, ACTH, and NE, effects that were prevented by pretreatment 1 week earlier with ICV shRNA for SDF-1 (nϭ6; Figure 6 ). The efficacy of the SDF-1 shRNA lentiviral particles was confirmed by Western blot analysis, using the brain tissues from the HF groups tested for neuroendocrine and hemodynamic effects of ICV SDF-1 shRNA or control shRNA. One week after ICV injection of the lentiviral particles, the HF rats treated with SDF-1 shRNA had significantly lower levels of SDF-1 protein in PVN and SFO than the HF rats treated with the scrambled shRNA control ( Figure S5 ).
Discussion
This study provides the first evidence to suggest that brain chemokines contribute to the regulation of cardiovascular function, sympathetic outflow, and neuroendocrine release in systolic HF. The novel findings of this study are as follows: (1) in rats with ischemia-induced HF, expression of the chemokine SDF-1 is upregulated in PVN and SFO, key cardiovascular regulatory regions of the forebrain; (2) HF rats have an exaggerated sympathetic response to ICV injection of SDF-1 or bilateral microinjection of SDF-1 into the PVN; (3) SDF-1 colocalizes with neuroendocrine (AVP and CRH) neurons in the PVN; (4) treatment with SDF-1 increases plasma AVP, ACTH, and NE levels in normal rats; and (5) shRNA to reduce endogenous SDF-1 expression in the brain reduces plasma AVP, ACTH, and NE in HF rats and attenuates the neuroendocrine responses to ICV SDF-1 in normal rats. SDF-1 and its CXCR4 receptor are expressed in microglia, astrocytes, and neurons of the PVN and SFO. Taken together, these findings strongly suggest that brain chemokines contribute to neural and humoral excitation in HF. Although not tested in this study, it seems likely that the overexpression of proinflammatory cytokines in the brain in this model of HF 15 promotes an overexpression of chemokines. The proinflammatory cytokines stimulate glial cells to produce chemokines in vitro, 16 and we have found that an ICV injection of the proinflammatory cytokine tumor necrosis factor-␣ increases the expression of SDF-1 in the PVN and SFO in normal rats. 17 Other factors that are increased in the brain in HF and have been reported to induce SDF-1 expression in the periphery, 18 including reactive oxygen species, angiotensin II, and aldosterone, may also stimulate chemokine production in the brain. ICV injection of SDF-1 elicited an exaggerated response in the HF rats, compared with SHAM, in the absence of increased numbers of CXCR4 receptors in the PVN or SFO. This finding suggests that the higher intrinsic levels of SDF-1 in PVN and SFO of HF rats, shown by immunofluorescence and confirmed by Western blot, render an otherwise subthreshold dose of exogenous SDF-1 sufficient to elicit a sympatho-excitatory response. This interpretation is sup- ported by the findings in normal rats pretreated with shRNA for SDF-1, demonstrating that reducing the basal SDF-1 expression prevented the humoral response and reduced the hemodynamic response to the higher ICV dose of SDF-1. Humoral factors play an important role in HF. Vasopressin is believed to contribute to the volume accumulation and hyponatremia that are prominent findings in severe systolic HF. 19 Previous work from our laboratory has shown activation of PVN CRH neurons in this model of HF. 20 CRH neurons are a marker of activation of the hypothalamic-pituitary-adrenal axis, with release of ACTH and activation of the sympathetic nervous system. The present study demonstrates colocalization of SDF-1 with AVP and CRH containing PVN neurons, upregulated expression of SDF-1 in HF rats, and a reduction in AVP and ACTH release in normal and HF rats when SDF-1 is targeted with shRNA. Taken together, these findings suggest that brain chemokines may contribute to the high circulating levels of neuroactive hormones found in this pathophysiological condition.
How exactly SDF-1 elicits sympathetic and neuroendocrine responses remains to be determined. SDF-1 may have both direct influences on the membrane potential of presympathetic or/and neuroendocrine neurons, as well as indirect influences. 6 SDF-1 is known to activate mitogen-activated protein kinase intracellular signaling pathways, 21 which we have found to play an important role in sympathetic activation in HF. 22 SDF-1 may be one of several excitatory mediators using mitogen-activated protein kinase as a common signaling pathway. In addition, chemokines can activate glial cells to produce cyclooxygenase-2 and prostaglandin E2, 23 which is sympatho-excitatory in the central nervous system. In preliminary studies, we have found that central administration of SDF-1 increased the expression of cyclooxygenase-2 in the PVN. The long duration of the SDF-1 effects suggests the possibility of genomic influences, in addition to synaptic and cellular mechanisms.
Finally, it is important to consider the potential sources of SDF-1 and other chemokines in pathophysiological states. Chemokines and their receptors are abundantly expressed in glial cells, 24 which have been implicated recently in activation of the sympathetic nervous system in hypertension 25 and HF. 26 In preliminary studies, we have found that SDF-1 is expressed in astrocytes ( Figure S1 ) and microglia ( Figure S2 ) in the HF rats, suggesting that glial cells may contribute substantially to chemokine-mediated neurohumoral excitation in that condition.
Limitations of the Study
In preliminary experiments in SHAM and HF rats, ICV administration of the CXCR4 antagonist AMD 3100 over a wide range of doses failed to block the hemodynamic and sympathetic responses to ICV SDF-1 and in fact elicited a paradoxical pressor response (see Figure S6) . As a result, we were unable to establish that CXCR4 is the only receptor mediating the cardiovascular and sympathetic responses to SDF-1. Others have reported that AMD 3100 was not effective in blocking the excitatory effects of SDF-1 on melanin-concentrating hormone neurons in the lateral hypothalamic area. 27 Those findings and ours suggest the possibility that the excitatory effects of SDF-1 may be mediated by an alternate receptor. Notable in that regard is a recent report that SDF-1 binds to an orphan G protein receptor called CXCR7 in T lymphocytes. 28 An important and confounding implication for future studies is that AMD 3100 may not be helpful in determining the role of SDF-1 in pathophysiological states like HF and hypertension. Nevertheless, in the present study, HF rats were clearly more sensitive to the effects of SDF-1 on sympathetic excitation, and shRNA for SDF-1 did reduce the plasma levels of AVP, ACTH and NE in HF rats and normal rats infused with SDF-1. These are convincing indications of the pathophysiological impact of proinflammatory chemokines in HF.
Finally, the immunohistochemical and microinjection data in this study identify the PVN as one central site at which SDF-1 can act to augment sympathetic drive and neuroendocrine release, but not as the only or even the primary site of SDF-1 action in pathophysiological states. SDF-1 is also expressed and upregulated in SFO in HF rats, and our limited preliminary studies indicate that it is amply expressed in SON ( Figure S3 ) and RVLM ( Figure S4 ) as well. All of these cardiovascular and autonomic regions are involved in neurohumoral regulation, and the interventions used in this study do not discriminate among them. Further work will be required to determine the predominant central site or sites of action of SDF-1.
Perspectives
The data presented here are the first evidence suggesting a potential role for brain chemokines in the regulation of autonomic function in HF. Although this study focused on the chemokine SDF-1, other chemokines are likely also involved. The significant effects on sympathetic drive, hemodynamic responses, and neuroendocrine release induced by ICV SDF-1 make a strong argument for chemokine regulation of autonomic and cardiovascular function in normal and pathophysiological conditions and suggest that brain chemokines, like the proinflammatory cytokines and the brain reninangiotensin system, play an important role in the pathogenesis of HF. It may be that chemokines mediate the responses to proinflammatory cytokines, which can stimulate chemokine production, 16, 17 in key brain regions like the PVN in which cytokine receptors appear to be relatively sparsely represented 29, 30 but chemokine receptors are abundant. 5 Fur- ther studies probing the role of brain chemokines will provide a better understanding of inflammatory mechanisms in HF and may lead to improvements in pharmaceutical treatment of this devastating disease. In addition to its relevance to cardiovascular diseases like HF and hypertension, this work opens new territory for the investigation of biological functions of chemokines in metabolic diseases like diabetes mellitus and obesity, in which inflammatory mediators are also critical contributing factors leading to neurohumoral and sympathetic activation. 
MATERIALS AND METHODS
Induction of heart failure and echocardiographic assessment
To produce the heart failure (HF) animal model, the left anterior descending coronary artery was ligated in rats under ketamine plus xylazine anesthesia (90 mg/kg+10 mg/kg, IP), as described previously.
1, 2 Sham-operated (SHAM) rats underwent the same surgical procedure without the coronary ligation. Within 24 hr after coronary artery ligation or sham surgery, rats were tranquilized with ketamine (75 mg/kg, IP) and left ventricular (LV) function was evaluated by two-dimensional echocardiography as previously described.
1, 2 The ischemic zone (IZ) as a percent of LV circumference (% IZ), LV ejection fraction, and LV end-diastolic volume were measured.
Preparation for electrophysiological and hemodynamic recording
Preparation of the animals for electrophysiological recording has been described in detail previously. 3, 4 In brief, after rats were anesthetized with urethane (1.5 g/kg, IP, supplemented as needed with 0.1g/kg), a catheter was implanted into left femoral artery to measure blood pressure (BP). A heating pad and heat lamp was used to maintain body temperature at 37 ± 1°C. Via a left flank incision, a renal nerve was exposed, dissected free from surrounding tissue, and placed on bipolar silver wire recording electrodes to record renal sympathetic nerve activity (RSNA). Nerve and electrodes were held together with Kwik-Cast silicon sealant (WPI, INC, Sarasota, FL) applied before the incisions were closed.
Preparation for intracerebroventricular (ICV) injections
To facilitate ICV injections with minimal injury to brain tissue, a guide cannula was implanted. The animal was fixed in a stereotaxic frame. The tip of a 29-gauge stainless steel guide cannula was positioned 2 mm above the left lateral cerebral ventricle using the following coordinates, with reference to bregma: anteroposterior, −1.0 mm; dorsoventral, −2.5 mm; mediolateral, -1.5 mm (left). ICV injections were made via a 33-gauge injection cannula inserted into the guide cannula and extended 2 mm beyond its tip. The injection cannula was connected to a 10 µl micro-syringe driven by a micropump (Harvard Apparatus, Holliston, MA).
Preparation for bilateral PVN microinjection
As previously described, 5 one 29-gauge guide cannula was placed 1.8 mm posterior to bregma, 0.4 mm left to midline for left PVN microinjection. Another 29 gauge guide cannula was placed 1.4 mm right to midline but angled 10° toward midline for right PVN microinjection. Both cannula tips were advanced to a final position 5.8 mm ventral to the cranial surface. Bilateral PVN microinjections were made via two 35-gauge (128 μm outer diameter, and 51.2 μm inner diameter) injection cannula inserted into the guide cannula and extended 2 mm beyond the tip of the guide cannula. Bilateral PVN microinjections (0.2 µl over 10 s) were made simultaneously using 1 μl Hamilton microsyringes. The microinjection sites were verified by 2% Pontamine sky blue (100nl) that was injected in the same locations at the end of experiments.
Data acquisition
A Cambridge Electronics Design laboratory interface (CED, model 1401; Cambridge, UK) connected to a personal computer was used to acquire the data. The raw RSNA was amplified by Grass preamplifier (Grass Instrument Co, Quincy, MA) and then was rectified and integrated by a Paynter filter (20-ms time constant, BAK Electronics; Germantown, MD) before being passed to the CED 1401 device. BP signals were transferred to CED 1401 via a pressure transducer and a Gould TA240S chart recorder (Gould Instruments, Valley. View, OH). HR was derived from the frequency of the arterial pressure pulses. Digitized data were stored for subsequent off-line analysis with Spike2 software (CED).
The electrophysiological and hemodynamic data were analyzed with Spike2 software (Cambridge Electronic Design, etc). Mean blood pressure (MBP, mmHg), HR (bpm), and integrated RSNA (mV) were averaged over 5 min intervals after ICV drug administration and compared with baseline values averaged over 5 min intervals immediately preceding each intervention. Changes in RSNA are reported as a percentage of baseline control. All values are expressed as the means ± SEM.
Drugs administered
1). For electrophysiological and hemodynamic recording studies. SDF-1/CXCL12 (CAT#: 350-NS-050/CF R&D System, Minneapolis, MN) was dissolved in artificial cerebrospinal fluid (aCSF). The doses of SDF-1 for injection were determined in preliminary experiments. Doses of 25 ng and 100 ng (in 2 µl aCSF) were selected for injection into the lateral cerebral ventricle. Doses of 2.5, 5, or 10 ng of SDF-1 (in 0.2 µl aCSF) were used for the bilateral PVN microinjections.
2). For neurohumoral studies. SDF-1 (50 ng/hour) was infused ICV for 4 hours in normal rats pretreated with ICV VEH (scrambled shRNA lentiviral particles: sc-108080, Santa Cruz, CA) or SDF-1 shRNA lentiviral particles (CAT#: sc-39367-V, Santa Cruz, CA). In HF rats, endogenous chemokine activity was reduced by ICV injection of SDF-1 shRNA lentiviral particles (CAT#: sc-39367-V, Santa Cruz, CA). Scrambled shRNA lentiviral particles (CAT#: sc-108080, Santa Cruz, CA) served as control. The doses of shRNA lentiviral particles were according to the manufacturer's instructions.
Brain tissue preparation
Rats were euthanized to collect brain tissues for immunofluorescence and Western analysis. To obtain tissues for immunostaining, rats were anesthetized with urethane (1.5 g/kg, IP) and transcardially perfused with 4% paraformaldehyde. Brains were then embedded with OCT and rapidly frozen in alcohol chilled dry ice. Coronal sections (16 μm) of target brain tissues were made with a cryostat and stored at −80 °C. To obtain tissues for Western blot, the animals were anesthetized with urethane (1.5 g/kg, IP) and decapitated. The brains were quickly removed, frozen in liquid nitrogen and stored at −80 °C. Coronal sections (300-μm) of the target tissues were made, and punched with a 15-gauge needle (inner diameter 1.5 mm). The punched tissues were homogenized in cell lysis buffer (Cell Signaling Technology, Beverly, MA) to extract protein for Western assay.
Western blot
Chemokine SDF-1/CXCL12 and its receptor CXCR4 were detected using polyclonal goat antibodies against SDF-1 (SC-6193, 1: 300, Santa Cruz, CA), and CXCR4 (SC-6190, 1: 300, Santa Cruz, CA), respectively. The second antibodies were goat anti-rabbit IgG-HRP (SC-2054, 1:5000, Santa Cruz) or rabbit anti-goat IgG-HRP (sc-2922, 1:5000, Santa Cruz). Immunoblots were visualized with an enhanced chemiluminescence reagent. The immunoblotting was quantified with NIH ImageJ software. The content of chemokines and their receptors was normalized by the total β-actin detected by rabbit monoclonal antibody (#4970, 1:1000; Cell Signaling Technology, Inc., Danvers, MA).
Immunofluorescence
Immunofluorescent double staining was used to examine the chemokine SDF-1/CXCL12 and its receptor CXCR4 expression in PVN and SFO neurons in SHAM and HF rats. The sections were incubated with the primary antibodies, the goat polyclonal antibodies to SDF-1 (SC-6193, 1: 100, Santa Cruz), and CXCR4 (SC-6190, 1: 100, Santa Cruz), and/or the mouse monoclonal antibody to neuronal marker NeuN (MAB377,1:300, Millipore) followed by secondary antibodies Alex Fluor 488 goat anti-rabbit IgG (A-11070, 1:200, Invitrogen) and Alex Fluor 568 goat anti-mouse IgG (A-11003, 1:200, Invitrogen). The specificity of the antibodies (SC-6193 and SC-6190) for immunofluorescent staining of SDF-1 and CXCR4 in rat brain tissue has been reported previously. [6] [7] [8] Immunofluorescent staining was visualized with a confocal laser-scanning microscope (Zeiss LSM 710, Carl Zeiss, Inc). Immunofluorescent intensity was quantified with NIH Image J software, as described previously. 9, 10 The fluorescent intensity of SDF-1 and CXCR4, expressed as arbitrary units (AU) per square micrometer, was measured in subregions of the PVN -dorsal parvocellular (PVN-dp), medial parvocellular (PVN-mp) ventrolateral parvocellular (PVN-vlp), and posterior magnocellular (PVN-pm) PVN 11 -and in the central region of SFO. The data for each region were acquired from three representative transverse sections in each animal and averaged to obtain a value for statistical analysis. To determine co-localization of AVP or CRH with SDF-1, the primary antibodies for AVP and CRH were rabbit polyclonal anti-vasopressin (AB1565, 1:300, Millipore, CA) and rabbit polyclonal anti-CRH (SC-10718, 1:300, Santa Cruz, CA).
ELISA measurement of plasma AVP and ACTH and NE concentration
Blood samples were collected from truck blood in EDTA tubes and were centrifuged for 20 min at 4 ○ C. The plasma was harvested and stored at -80 ○ C for future use. Plasma AVP, ACTH and NE concentrations were measured using standard arg 8 -Vasopressin ELISA kit (Cat# 900-017, Assay Designs, MI), Adrenocorticotropic Hormone ELISA kit (Cat# AC018T, Calbiotech) and Noradrenaline Research ELISA kit (CAT# BA 10-5200, LDN, Germany), respectively. The experimental procedures for ELISA were performed according to the manufacturers' manuals. 
